Literature DB >> 31053683

Immuno-PET to Optimize the Dose of Monoclonal Antibodies for Cancer Therapy: How Much Is Enough?

Raymond M Reilly1.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 31053683      PMCID： PMC6604693          DOI： 10.2967/jnumed.119.225854

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  16 in total

Review 1.  Clinical pharmacokinetics of therapeutic monoclonal antibodies.

Authors:  Ron J Keizer; Alwin D R Huitema; Jan H M Schellens; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2010-08       Impact factor: 6.447

Review 2.  Monoclonal antibodies--regulatory challenges.

Authors:  Christian K Schneider
Journal:  Curr Pharm Biotechnol       Date:  2008-12       Impact factor: 2.837

Review 3.  Therapeutic antibodies against cancer.

Authors:  Mark J Adler; Dimiter S Dimitrov
Journal:  Hematol Oncol Clin North Am       Date:  2012-06       Impact factor: 3.722

Review 4.  Antibody positron emission tomography imaging in anticancer drug development.

Authors:  Laetitia E Lamberts; Simon P Williams; Anton G T Terwisscha van Scheltinga; Marjolijn N Lub-de Hooge; Carolien P Schröder; Jourik A Gietema; Adrienne H Brouwers; Elisabeth G E de Vries
Journal:  J Clin Oncol       Date:  2015-03-16       Impact factor: 44.544

Review 5.  Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies.

Authors:  Diego Tosi; Yassine Laghzali; Marie Vinches; Marie Alexandre; Krisztian Homicsko; Angelica Fasolo; Gianluca Del Conte; Anna Durigova; Nadia Hayaoui; Sophie Gourgou; Luca Gianni; Caroline Mollevi
Journal:  J Clin Oncol       Date:  2015-05-26       Impact factor: 44.544

6.  Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates.

Authors:  Eva J Razumienko; Deborah A Scollard; Raymond M Reilly
Journal:  J Nucl Med       Date:  2012-10-24       Impact factor: 10.057

Review 7.  Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example.

Authors:  Jeffrey R Sachs; Kapil Mayawala; Satvik Gadamsetty; Soonmo Peter Kang; Dinesh P de Alwis
Journal:  Clin Cancer Res       Date:  2015-11-23       Impact factor: 12.531

8.  Phase 1 Evaluation of [(64)Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors.

Authors:  A Craig Lockhart; Yongjian Liu; Farrokh Dehdashti; Richard Laforest; Joel Picus; Jennifer Frye; Lauren Trull; Stefanie Belanger; Madhuri Desai; Syed Mahmood; Jeanne Mendell; Michael J Welch; Barry A Siegel
Journal:  Mol Imaging Biol       Date:  2016-06       Impact factor: 3.488

9.  Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.

Authors:  G Gebhart; L E Lamberts; Z Wimana; C Garcia; P Emonts; L Ameye; S Stroobants; M Huizing; P Aftimos; J Tol; W J G Oyen; D J Vugts; O S Hoekstra; C P Schröder; C W Menke-van der Houven van Oordt; T Guiot; A H Brouwers; A Awada; E G E de Vries; P Flamen
Journal:  Ann Oncol       Date:  2015-11-23       Impact factor: 32.976

Review 10.  Mechanistic considerations for the use of monoclonal antibodies for cancer therapy.

Authors:  Patrick M Glassman; Joseph P Balthasar
Journal:  Cancer Biol Med       Date:  2014-03       Impact factor: 4.248
View more
  1 in total

1.  Dose escalation PET imaging for safety and effective therapy dose optimization of a bispecific antibody.

Authors:  Yan Wang; Donghui Pan; Chenrong Huang; Bingliang Chen; Mingzhu Li; Shuaixiang Zhou; Lizhen Wang; Min Wu; Xinyu Wang; Yicong Bian; Junjie Yan; Junjian Liu; Min Yang; Liyan Miao
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.